Seeking Market-Beating Returns: GlaxoSmithKline plc Stands Out

GlaxoSmithKline plc (LON:GSK) is one investment worth considering, argues Alessandro Pasetti.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), British American Tobacco (LSE: BATS), Next (LSE: NXT) and Royal Mail (LSE: RMG) offer a return on equity higher than 40%, based on their trailing figures. A different risk profile is associated to each business — but GSK stands out.

GlaxoSmithKline Leads The Pack

After a long chat with a friend in the City who has been a pharma analyst for ages and knows the industry inside out, I wondered: what would I not like about GSK if I were to bet on a pharma company today?

GlaxoSmithKlineGSK is a cash machine with a strong market share in the industry. The stock is flat for the year; it’s down 5% in the last 12 months; and it’s up only 10% in the last two years. There is more to it.

“GSK doesn’t have that big a patent cliff to speak of – certainly nowhere near as big as the likes of AstraZeneca or Eli Lilly & Co.,” my friend pointed out.

With regard to the latest round of bad publicity, i.e. the recent scandal in China, he noted: “(GSK is) not affected at all. This is a good scandal story for mainstream press, but the investment community basically sees this as the ‘cost of doing business’ in places like China.”

And what about GSK’s latest corporate activity?

“Well, oncology is the number one area for R&D today. Full stop. And through the Novartis deal, GSK seems to be signalling that it’s getting out of it. True, its products will probably sit better at Novartis, which has a bigger presence (…),” he started.

“I’d suggest that internally GSK in fact has no intention at all of getting out of oncology – it would be mad to – and will instead do more licensing in now to bolster its pipeline,” he concluded.

If anybody thinks AstraZeneca’s valuation is justified, then GSK should trade a lot higher, we both agreed.

GSK could be bought for tax reasons, “though even Pfizer doesn’t need a takeover as big as this to do an inversion,” he reminded me. Of course, GSK stock doesn’t price in an M&A premium, but a takeover of GSK is very unlikely.

Finally, GSK’s capital structure is much more efficient than that of other rivals.

British American Tobacco, Next and Royal Mail

At a time the stock market trades at all-time highs, BAT is certainly a defensive stock to hold as part of a diversified portfolio. Its revenue growth trajectory is not terrific, but its operating margin and free-cash-flow yield are truly impressive. BAT’s balance sheet can be levered up, which leaves plenty of room for shareholder-friendly activity. The tobacco industry may be a play on consolidation, which could also help boost the value of several players in the industry.

Elsewhere, most retailers have been hammered in recent weeks. Next is holding up relatively well and, it must be noted, has been a takeover target for some time. Bullish estimates for top-line growth into 2017 are reasonable; operating profitability is in the region of 19% and is growing fast; its bottom line has expanded for years, and earnings per share are expected to grow in future; and its balance sheet is healthy.

Of all, Royal Mail is the less compelling investment case as it’ll need to prove that it can remain profitable without losing competitiveness in the UK. And that is certainly not a given…

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro does not own shares in any of the companies mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »